• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

24 小时血压和心率对左心室射血分数降低和中值的患者预后的影响。

Effect of 24-hour blood pressure and heart rate on the prognosis of patients with reduced and midrange LVEF.

机构信息

Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia Faculty of Fundamental Medicine, Lomonosov Moscow State University, Russia.

Academician Chapidze Center for Emergency Cardiology, Tbilisi, Georgia.

出版信息

Kardiologiia. 2021 Jul 31;61(7):4-13. doi: 10.18087/cardio.2021.7.n1684.

DOI:10.18087/cardio.2021.7.n1684
PMID:34397336
Abstract

Aim    Optimal combination therapy for chronic heart failure (CHF) currently implies the mandatory use of at least four classes of drugs: renin-angiotensin-aldosterone (RAAS) system inhibitors or angiotensin receptor blocker neprilysin inhibitors (ARNI); beta-adrenoblockers (BAB); mineralocorticoid receptor antagonists; and sodium-glucose cotransporter 2 inhibitors. Furthermore, many of these drugs are able to decrease blood pressure even to hypotension and alleviate tachycardia. This study focused on the relationship of 24-h blood pressure (BP) and heart rate (HR) with the prognosis for CHF patients with sinus rhythm and left ventricular ejection fraction (LV EF) <50 % as well as on suggesting possible variants of safe therapy for CHF depending on the combination of studied factors.Material and methods    Effects of clinical data, echocardiographic parameters, 24-h BP, and heart rhythm (data from 24-h BP and ECG monitors) on the prognosis of 155 patients with clinically pronounced CHF, LV EF <50 %, and sinus rhythm who were followed up for 5 years after discharge from the hospital.Results    The one-factor analysis showed that the prognosis of CHF patients was statistically significantly influenced by the more severe functional class (FC) III CHF compared to FC II, reduced LV EF (<35 %), a lower 24-h systolic BP (SBP) (<103 mm Hg), the absence of hypotensive episodes in daytime, a low variability of nighttime BP (<7.5 mm Hg), a higher 24-h HR (>71 bpm vs. <60 bpm), the absence of therapy with RAAS inhibitors + BAB, and a lower body weight index. The multi-factor analysis showed that more severe CHF FC, lower LV EF, and the absence of RAAS inhibitors + BAB therapy retained the influence on the prognosis. After eliminating the influencing factor of drug therapy, also a low SBP variability significantly influenced the prognosis. An additional analysis determined the following four groups of CHF patients with reduced heart systolic function according to mean 24-h HR and SBP: the largest group (38.1 % of all patients) with controlled HR (≤69 bpm), preserved SBP (>103 mm Hg), and the lowest death rate of 15.3 %; the group with increased HR (>69 bpm) but preserved SBP (30.3 % of all patients) where the death rate was 44.7 %, which was significantly higher than in the first group; the group with normal HR (≤69 bpm) but reduced SBP (≤103 mm Hg) (16.1 % of patients) where the death rate was 40 %, which was comparable with the second group and significantly worse than in the first group; and the group with both increased HR (>69 bpm) and reduced SBP (≤103 mm Hg) (15.5 % of patients), which resulted in the maximal risk of death (70.8 % of patients with CHF and LV EF <50 %), which was significantly higher than in the three other groups.Conclusion    Low SBP (including 24-h SBP with reduced variability in day- and nighttime) in combination with high HR (including by data of Holter monitoring), low LV EF, more severe clinical course of CHF, and the absence of an adequate treatment with neurohormonal modulators (RAAS inhibitors and BAB) significantly increased the risk of death. Isolating four types of FC II-III CHF with sinus rhythm and EF <50% based on the combination of HR and BP identifies patients with an unfavorable prognosis, which will help developing differentiated therapeutic approaches taking into account clinical features.

摘要

目的

慢性心力衰竭(CHF)的最佳联合治疗目前意味着必须至少使用四类药物:肾素-血管紧张素-醛固酮(RAAS)系统抑制剂或血管紧张素受体脑啡肽酶抑制剂(ARNI);β-肾上腺素能阻滞剂(BAB);盐皮质激素受体拮抗剂;以及钠-葡萄糖共转运蛋白 2 抑制剂。此外,许多这些药物能够降低血压,甚至降低至低血压,并缓解心动过速。本研究侧重于 24 小时血压(BP)和心率(HR)与窦性节律和左心室射血分数(LV EF)<50%的 CHF 患者预后的关系,以及根据研究因素的组合,为 CHF 提出可能的安全治疗方案。

材料和方法

对 155 例临床显著 CHF、LV EF <50%和窦性节律患者的临床数据、超声心动图参数、24 小时 BP 和心律(24 小时 BP 和心电图监测数据)对预后的影响进行了分析。这些患者在出院后随访了 5 年。

结果

单因素分析显示,CHF 患者的预后受到更严重的功能分级(FC)III CHF 的统计学显著影响,与 FC II 相比,LV EF 降低(<35%),24 小时收缩压(SBP)较低(<103mmHg),白天无低血压发作,夜间 BP 变异性较低(<7.5mmHg),24 小时 HR 较高(>71bpm 与 <60bpm),未接受 RAAS 抑制剂+BAB 治疗,体重指数较低。多因素分析显示,更严重的 CHF FC、更低的 LV EF 和缺乏 RAAS 抑制剂+BAB 治疗仍然对预后有影响。在消除药物治疗的影响因素后,SBP 变异性较低也显著影响预后。进一步的分析根据平均 24 小时 HR 和 SBP 确定了具有降低心脏收缩功能的四个 CHF 患者组:最大组(所有患者的 38.1%)具有控制的 HR(≤69bpm)、保留的 SBP(>103mmHg)和最低的死亡率为 15.3%;HR 升高(>69bpm)但 SBP 保留(所有患者的 30.3%)的组死亡率为 44.7%,明显高于第一组;HR 正常(≤69bpm)但 SBP 降低(≤103mmHg)(16.1%的患者)的组死亡率为 40%,与第二组相当,但明显高于第一组;以及 HR 升高(>69bpm)和 SBP 降低(≤103mmHg)的组(所有患者的 15.5%),导致死亡风险最高(LV EF <50%的 CHF 患者为 70.8%),明显高于其他三组。

结论

低 SBP(包括昼夜 SBP 变异性降低)与高 HR(包括动态心电图监测数据)、低 LV EF、更严重的 CHF 临床过程以及神经激素调节剂(RAAS 抑制剂和 BAB)治疗不足相结合,显著增加了死亡风险。基于 HR 和 BP 的组合,将窦性节律和 EF <50%的 FC II-III CHF 分为四种类型,可以识别预后不良的患者,这将有助于制定考虑临床特征的差异化治疗方法。

相似文献

1
Effect of 24-hour blood pressure and heart rate on the prognosis of patients with reduced and midrange LVEF.24 小时血压和心率对左心室射血分数降低和中值的患者预后的影响。
Kardiologiia. 2021 Jul 31;61(7):4-13. doi: 10.18087/cardio.2021.7.n1684.
2
[Analysis of mortality in patients with heart failure after de-compen-sation during long-term follow-up in specialized medical care and in real clinical practice].[在专业医疗护理及实际临床实践中对心力衰竭失代偿患者长期随访期间死亡率的分析]
Kardiologiia. 2020 Mar 2;60(4):91-100. doi: 10.18087/cardio.2020.4.n1014.
3
[Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction].伊伐布雷定用于治疗射血分数保留的心力衰竭
Kardiologiia. 2020 Oct 10;60(10):33-37. doi: 10.18087/cardio.2020.10.n1324.
4
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].[不同神经激素调节剂三联组合推荐用于治疗轻至中度充血性心力衰竭患者吗?(Sadko-CHF研究结果)]
Ter Arkh. 2006;78(8):14-20.
5
[Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].[螺内酯长期治疗对接受最佳治疗的心力衰竭患者24小时心律变异性参数和室性心律失常的影响]
Kardiologiia. 2008;48(2):52-64.
6
Predictors of tachycardia-induced cardiomyopathy in patients with first-time decompensation of chro-nic heart failure with reduced left ventricular ejection fraction of nonischemic etiology and persistent atrial tachyarrhythmia.预测非缺血性病因和持续性房性快速性心律失常导致左心室射血分数降低的慢性心力衰竭首次失代偿患者的心动过速性心肌病。
Kardiologiia. 2022 Nov 30;62(11):56-62. doi: 10.18087/cardio.2022.11.n2262.
7
The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.现代疗法改善心力衰竭患者预后的能力:血管紧张素-中性肽链内切酶抑制剂和钠-葡萄糖协同转运蛋白抑制剂的作用
Kardiologiia. 2021 Jul 1;61(6):4-10. doi: 10.18087/cardio.2021.6.n1678.
8
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].[不同神经激素调节剂三联组合推荐用于治疗轻至中度充血性心力衰竭患者吗?(SADKO-CHF研究结果)。第2部分]
Ter Arkh. 2006;78(9):61-71.
9
[Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].[长期应用螺内酯对接受优化治疗的中重度慢性心力衰竭患者的疗效及安全性]
Kardiologiia. 2007;47(10):12-23.
10
[Influence of Omega-3 PUFA on Non-invasive factors determining the risk of arrhYthmias eXcess and sudden cardiac death in patients with HFpEF with ischemic etiology (ONYX)].ω-3多不饱和脂肪酸对缺血性病因的射血分数保留型心力衰竭(HFpEF)患者心律失常过多和心源性猝死风险的非侵入性决定因素的影响(ONYX研究)
Kardiologiia. 2020 Nov 12;60(10):86-98. doi: 10.18087/cardio.2020.10.n1327.